Papachristos A - Search Results

1

Machine learning-guided covariate selection for time-to-event models developed from a small sample of real-world patients receiving bevacizumab treatment.

Karatza E, Papachristos A, Sivolapenko GB, Gonzalez D. Karatza E, et al. Among authors: papachristos a. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1328-1340. doi: 10.1002/psp4.12848. Epub 2022 Aug 4. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35851999 Free PMC article.

2

Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.

Papachristos A, Pippa N, Ioannidis K, Sivolapenko G, Demetzos C. Papachristos A, et al. J Liposome Res. 2015;25(2):166-73. doi: 10.3109/08982104.2014.950277. Epub 2014 Aug 22. J Liposome Res. 2015. PMID: 25148295 Review.

3

Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.

Papachristos A, Pippa N, Demetzos C, Sivolapenko G. Papachristos A, et al. Drug Deliv. 2016 Jun;23(5):1662-6. doi: 10.3109/10717544.2014.998323. Epub 2015 Jan 27. Drug Deliv. 2016. PMID: 25625494 Review.

4

VEGF-A and ICAM-1 Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer.

Papachristos A, Kemos P, Katsila T, Panoilia E, Patrinos GP, Kalofonos H, Sivolapenko GB. Papachristos A, et al. Int J Mol Sci. 2019 Nov 18;20(22):5791. doi: 10.3390/ijms20225791. Int J Mol Sci. 2019. PMID: 31752122 Free PMC article.

5

Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.

Papachristos A, Kemos P, Kalofonos H, Sivolapenko G. Papachristos A, et al. Oncologist. 2020 Oct;25(10):853-858. doi: 10.1634/theoncologist.2019-0835. Epub 2020 Apr 28. Oncologist. 2020. PMID: 32272489 Free PMC article.

6

Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.

Papachristos A, Karatza E, Kalofonos H, Sivolapenko G. Papachristos A, et al. Int J Mol Sci. 2020 May 26;21(11):3753. doi: 10.3390/ijms21113753. Int J Mol Sci. 2020. PMID: 32466535 Free PMC article.

7

Pharmacogenomics, Pharmacokinetics and Circulating Proteins as Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review.

Papachristos A, Sivolapenko GB. Papachristos A, et al. J Pers Med. 2020 Aug 4;10(3):79. doi: 10.3390/jpm10030079. J Pers Med. 2020. PMID: 32759686 Free PMC article. Review.

8

In Reply.

Papachristos A, Kemos P, Kalofonos H, Sivolapenko G. Papachristos A, et al. Oncologist. 2020 Dec;25(12):e2023. doi: 10.1002/onco.13565. Epub 2020 Oct 26. Oncologist. 2020. PMID: 33044037 Free PMC article.

9

Do we need to adopt antifungal stewardship programmes?

Ioannidis K, Papachristos A, Skarlatinis I, Kiospe F, Sotiriou S, Papadogeorgaki E, Plakias G, Karalis VD, Markantonis SL. Ioannidis K, et al. Among authors: papachristos a. Eur J Hosp Pharm. 2020 Jan;27(1):14-18. doi: 10.1136/ejhpharm-2017-001467. Epub 2018 Jun 28. Eur J Hosp Pharm. 2020. PMID: 32064083 Free PMC article.

10

Personalizing chemotherapy dosing using pharmacological methods.

Patel JN, Papachristos A. Patel JN, et al. Among authors: papachristos a. Cancer Chemother Pharmacol. 2015 Nov;76(5):879-96. doi: 10.1007/s00280-015-2849-x. Epub 2015 Aug 23. Cancer Chemother Pharmacol. 2015. PMID: 26298089 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

97 results

Search Page